• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Neuberger Berman High Yield Strategies

Neuberger Berman High Yield Strategies

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. NHS Scotland's Golden Jubilee National Hospital Uses MicroStrategy to Improve Operations and Enhance Patient Care

    NHS Scotland's Golden Jubilee National Hospital Uses MicroStrategy to Improve Operations and Enhance Patient Care

  2. First Hospital Light Fixture to Kill Bacteria Safely and Continuously Becomes Commercially Available in U.S. and Canada

    First Hospital Light Fixture to Kill Bacteria Safely and Continuously Becomes Commercially Available in U.S. and Canada

  3. Research and Markets: United Kingdom Medical Insurance Report 2015

    Research and Markets: United Kingdom Medical Insurance Report 2015

  4. Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler® (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla™ in the UK

    Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler® (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla™ in the UK

  5. Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis

    Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis

  6. CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA

    CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA

  7. New Synexus Board Gears up for Expansion Through Organic Growth and Acquisition

    New Synexus Board Gears up for Expansion Through Organic Growth and Acquisition

  8. Omicia Wins UK's 100,000 Genomes Project as Clinical Interpretation Provider

    Omicia Wins UK's 100,000 Genomes Project as Clinical Interpretation Provider

  9. Japan Equity CEFs Win the First Quarter

    These closed-end funds were unstoppable in early 2015; plus, did the first IPO of 2015 usher in a new era for CEF shareholders?

  10. Observations about Neuberger Berman Closed-End Fund Tender Offers

    Dan Plettner invests and receives income for securities research, including “buy-side” research. Dan licenses his own real time trading data to Covestor Ltd. (“Covestor”), frequently including positions discussed in his Morningstar Contributions. Covestor is a Registered Investment Advisor that ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.